Highlights of recent findings on quality-of-life management for patients with cancer and their survivors

JAMA Oncology

Volumn 2, Issue 11, 2016, Pages 1401-1402

  Shapiro, Charles L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED; HUMAN; NEOPLASMS; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVOR;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVORS;

EID: 85013119872     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3620     Document Type: Short Survey

References (10)

1. Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials [published online June 20, 2016]. J Clin Oncol. 2016;JCO662346. doi:10.1200/JCO.2015.66.2346.
2. Kleckner I, Kamen CS, Peppone LJ, et al. A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients. ASCO Meeting Abstracts; June 3-7, 2016; Chicago, IL: Abstract 10 000.
3. Temel JS, El-Jawahri A, Greer JA, et al. Randomized trial of early integrated palliative and oncology care. ASCO Meeting Abstracts; June 3-7, 2016; Chicago, IL: Abstract 10 003.
4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363 (8):733-742.
5. Bekelman JE, Halpern SD, Blankart CR, et al; International Consortium for End-of-Life Research (ICELR). Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA. 2016;315(3):272-283.
6. Wright AA, Keating NL, Ayanian JZ, et al. Family perspectives on aggressive cancer care near the end of life. JAMA. 2016;315(3):284-292.
7. Bomba PA, Kemp M, Black JS. POLST: An improvement over traditional advance directives. Cleve Clin J Med. 2012;79(7):457-464.
8. KnestrickMW, Pedraza SL, Culp S, Falkenstine EC, Moss AH. Benefits of physician orders for scope of treatment (POST) forms on end-of-life care in cancer patients: insights from theWest Virginia registry. ASCO Meeting Abstracts; June 3-7, 2016; Chicago, IL: Abstract 10 006.
9. Wilkinson A, Wenger N, Sugarman LR; Rand Corporation. Literature review on advance directives. 2007. https://aspe.hhs.gov/basic-report/literature-review-Advance-directives. Accessed August 8, 2016.
10. Hickman SE, Keevern E, Hammes BJ. Use of the physician orders for life-sustaining treatment program in the clinical setting: A systematic review of the literature. J AmGeriatr Soc. 2015;63(2): 341-350.